2.1 Million Cardiac Rhythm Patients in Indonesia Spikes the Beat of the CRM Market, Finds Frost & Sullivan
JAKARTA, Indonesia, June 20, 2012 /PRNewswire/ – Indonesia has a high prevalence of both communicable and non-communicable diseases; among non-communicable diseases, cardiovascular disease’s incidence is 7.2 per cent of the total population of 247 million and it is also the fourth leading cause of mortality. Of these, 2.1 million suffer from disorders caused by the rhythm of heart, signifying vast opportunities for the cardiac rhythm management (CRM) market on a small base.
New analysis from Frost & Sullivan (http://www.medicaldevices.frost.com), Indonesian Market for Cardiac Rhythm Management, finds that the market earned revenues of $1.75 million in 2011 and estimates this to reach $4.15 million in 2016 at a compound annual growth rate of 18.9 per cent.
The occurrence of cardiovascular diseases is on the rise due to sedentary lifestyles, unhealthy eating habits and urbanization. However, changes in healthcare services legislation, revamp in health insurance policies, an aging population, affluent and dormant life style, smoking and the urge to be treated will boost the Indonesian CRM market.
In 2011, single-chamber pacemakers were the most popular device for CRM due to their low cost, familiarity and simplicity of implantation.
“Both hospitals and healthcare professionals have indicated a preference for pacemakers, making it the largest segment, with a sale of 417 units, accounting for 49.6 per cent of the Indonesian CRM market,” says Frost & Sullivan’s Consultant, Poornima Srinivasan.
Pacemakers will gain further traction with its use in cardiac resynchronization therapy due to the product’s success rates, efficacy and longevity.
Currently, there are limited interventional cardiology and electrophysiology centres to perform cardiac rhythm implants.
“To meet the needs of the growing incidence, the Indonesian government is encouraging private hospitals and foreign participants to establish hospitals in the country,” notes Srinivasan.
“As the rising wealth and population growth necessitate quality healthcare services in Indonesia, the government has decided to extend the maximum limit for foreign ownership from 47 percent to 67 percent. As a result of this legislation, more foreign hospitals with sophisticated technologies and infrastructure are expected to invest in Indonesia,” says Eugene van de Weerd, Country Director, Frost & Sullivan – Indonesia. “Such a move is expected to result in more cardiac, oncological, and other surgeries taking place within the country, thereby curtailing the need for medical treatment abroad.” Eugene concluded.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Corporate Communications – Indonesia
P : +6221 571 0838
F : +6221 5713246
E : firstname.lastname@example.org
SOURCE Frost & Sullivan